Major congenital malformations

1. SGLT2 inhibitors have no effect on major congenital malformations in humans (RR 0.94, 95% CI 0.68-1.29).

   “SGLT2 inhibitor exposure was not associated with major congenital malformations (RR 0.94, 95% CI 0.68-1.29) or cardiac malformations (RR 0.97, 95% CI 0.64-1.48).”

   ReviewEarly-pregnancy exposure in women with type 2 diabetes; insulin comparatorfemales

   Periconceptional and early-pregnancy exposure to SGLT2 inhibitors and congenital malformations: a systematic review and meta-analysis

   Endocrine·Oct 17, 2026

More on SGLT2 inhibitors